XML 59 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 15, 2016
Feb. 09, 2015
Jul. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Feb. 29, 2016
Personnel cost       $ 158,140 $ 41,991 $ 166,550 $ 236,594  
Due to related party       200,333   83,166 59,525  
Warrants issued for remaining debt amount       178,572   47,791 36,470  
Accounts payable       618,756   663,261 10,980  
Accrued expenses       717,547   1,393,521 64,688  
Accrued Interest Payable       21,225   14,475    
Warrant liability             36,470  
Debt instrument face amount           121,523    
Chairman Of Board [Member] | Line Letter [Member]                
Line of credit current borrowing capacity $ 540,000         250,000    
Line of credit maturity date Apr. 30, 2017              
Trieu [Member] | Line Letter [Member]                
Line of credit $ 250,000     475,064        
Line of credit, percentage 5.00%              
Debt conversion description Dr. Trieu has the right, exercisable by delivery of written notice thereof (the “Election Notice”), to either: (i) receive repayment for the entire unpaid principal amount advanced under the Line Letter and the accrued and unpaid interest thereon on the date of the delivery of the Election Notice (the “Outstanding Balance”) or (ii) convert the Outstanding Balance into such number of shares of our common stock as is equal to the quotient obtained by dividing (x) the Outstanding Balance by (y) $0.10 (such price, the “Conversion Price”); provided, that in no event shall the Conversion Price be lower than the lower of (x) $0.28 per share or (y) the lowest exercise price of any securities that have been issued by us in a capital raising transaction (and that would otherwise reduce the exercise price of any other outstanding warrants issued by us) during the period between November 15, 2016 and the date of the delivery of the Election Notice. No capital raising transactions have occurred through the date of this filing with securities at a price lower than $0.28 per share.              
IthenaPharma Inc [Member]                
Debt instrument maturity date     Jun. 30, 2018          
IthenaPharma Inc [Member] | Investor [Member]                
Debt instrument face amount     $ 50,000          
Debt instrument interest rate     3.00%          
Shares issued price per share     $ 1.80          
Related Party [Member] | IthenaPharma Inc [Member]                
Due to related party $ 5,375              
Investment 479              
Accounts payable 71,560              
Accrued expenses 11,470              
Other liabilities 118,759              
Convertible note 50,000              
Accrued Interest Payable 567              
Contributed capital 257,252              
Autotelic [Member]                
Billed expenses       $ 213,103 $ 72,231 344,563 332,866  
Payment of billed expenses           $ 232,610 $ 278,716  
Warrant liability $ 118,759              
Autotelic [Member] | January 1 to March 31, 2015 [Member]                
Service provider percentage             100.00%  
Issuance of warrants             47,374  
Warrants exercise price             $ 2.76  
Autotelic [Member] | April 1 To June 30, 2015 [Member]                
Service provider percentage             100.00%  
Issuance of warrants             40,132  
Warrants exercise price             $ 2.76  
Autotelic [Member] | July,1 to September 2015 [Member]                
Service provider percentage             100.00%  
Issuance of warrants             30,214  
Warrants exercise price             $ 2.76  
Autotelic [Member] | October 1 to December 31, 2015 [Member]                
Service provider percentage   100.00%            
Issuance of warrants               21,453
Warrants exercise price               $ 2.76
Master Services Agreement [Member]                
Ownership interest       10.00%   10.00%    
Proceeds from common or preferred stock, gross       $ 10,000,000   $ 10,000,000    
Provider services description       After the Equity Financing Date, the Company shall pay Autotelic a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations (“CMO”), U.S. Food & Drug Administration (“FDA”) regulatory process, Contract Research Organizations (“CRO”) and Chemistry and Manufacturing Controls (“CMC”).   After the Equity Financing Date, the Company shall pay Autotelic a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations (“CMO”), U.S. Food & Drug Administration (“FDA”) regulatory process, Contract Research Organizations (“CRO”) and Chemistry and Manufacturing Controls (“CMC”).    
Master Services Agreement [Member] | Related Party [Member]                
Service provider percentage       20.00%   20.00%